Valeo Pharma Inc. (VPH.C) announced today that it has successfully entered into a Product Listing Agreement (PLA) with the Quebec Minister of Health. According to this agreement, the Company…
Redesca
In this episode, we revisit Valeo Pharma (VPH.C) to get an update on their product portfolio, stock price, and financials. Is VPH.C a good long term investment? Tune In!…
Valeo Pharma (VPH.C) announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura…
Valeo Pharma’s (VPH.C) low molecular weight heparin (LMWH) drug, Redesca and Redesca HP, is now eligible for public reimbursement in seven provinces and territories across Canada, as well as…
Valeo Pharma (VPH.C) announced they have entered into a Product Listing Agreement (PLA) with the Executive Officer of the Ontario Public Drug Program for the listing of Redesca and…
Valeo Pharma (VPH.C) announced they have begun shipments across Canada of Redesca and Redesca HP, their low molecular weight heparin (LMWH) biosimilar. Valeo has licensed Redesca from Shenzhen Techdow…
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement…